AI could spot diabetic eye disease in minutes

NCT ID NCT06721351

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using artificial intelligence (AI) to screen for diabetic retinopathy is faster and more accessible than the usual method with an eye doctor. About 548 adults with diabetes will be randomly assigned to either standard screening or AI-based screening using a special camera and EyeArt® system. Researchers will compare completion rates, time spent, and patient satisfaction over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EyeArt® AI system for diabetic retinopathy screening
What this could lead to
If successful, this could make diabetic eye screenings quicker and more widely available, especially in community clinics, helping catch vision-threatening problems earlier.
What could go wrong
This is a single-site study with 548 participants, so results may not apply everywhere. The AI may not work as well in all real-world settings or for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY, DR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • San Ysidro Health - Comprehensive Health Center - Ocean View

    San Diego, California, 92113, United States

  • San Ysidro Health Chula Vista

    Chula Vista, California, 91910, United States

  • San Ysidro Health King-Chavez Health Center

    San Diego, California, 92114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.